Virios Therapeutics Q2 EPS $(0.08) Misses $(0.07) Estimate
Portfolio Pulse from sunil@benzinga.com
Virios Therapeutics reported Q2 losses of $(0.08) per share, missing the analyst consensus estimate of $(0.07) by 14.29%. However, this is an 81.82% increase over losses of $(0.44) per share from the same period last year.
August 10, 2023 | 11:10 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Virios Therapeutics' Q2 earnings per share missed estimates, which could negatively impact the stock price in the short term.
Virios Therapeutics reported a larger loss than expected for Q2, missing analyst estimates. This could lead to a decrease in investor confidence and a potential drop in the stock price in the short term. However, the YoY improvement might mitigate some of the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100